Federal Register of Legislation - Australian Government

Primary content

PB 8 of 2012 Arrangements as made
This instrument amends the National Health (Growth Hormone Program) Special Arrangement 2011 (No. PB 88 of 2011) to make changes to the special arrangements relating to the Growth Hormone Program.
Administered by: Health
Made 27 Feb 2012
Registered 28 Feb 2012
Tabled HR 01 Mar 2012
Tabled Senate 01 Mar 2012
Date of repeal 19 Mar 2014
Repealed by Health (Spent and Redundant Instruments) Repeal Regulation 2014

PB 8 of 2012

National Health (Growth Hormone Program) Special Arrangement Amendment Instrument 2012 (No.1)

National Health Act 1953

I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this Instrument under subsections 100(1) and 100(2) of the National Health Act 1953.

Dated  27   February 2012

 

 

 

 

 

 

 

 

 

FELICITY McNEILL

First Assistant Secretary

Pharmaceutical Benefits Division

Department of Health and Ageing


1          Name of Instrument

            (1)        This Instrument is the National Health (Growth Hormone Program)

                        Special Arrangement Amendment Instrument 2012 (No.1).

            (2)        This Instrument may also be cited as PB 8 of 2012.

2          Commencement

(1)       Sections 1 to 3 and Schedule 1 are taken to have commenced on
          
1 December 2011.

(2)       Schedule 2 commences on 1 March 2012.

3          Amendment of PB 88 of 2011

            Schedules 1 and 2 amend the National Health (Growth Hormone Program) Special Arrangement 2011 (PB 88 of 2011).

 


 

 

 

 


Schedule 1     Amendments

 

[1]           Subsection 47(2),

substitute:

 

(2)   However, if the form of the pharmaceutical benefit and the manufacturer’s pack is unable to accommodate the dose level mentioned

              in the item of the table that applies to a person, the dose of pharmaceutical benefit that the Secretary determines:

 

(a)    for a person eligible for the maximum dose level of an item of the table – may be within 3% of the maximum dose level of the item of the table that applies to the person; or

(b)   for any other person – may be the closest available dose to a dose level mentioned in the table that applies to the person.

 

(2A) If paragraph (2)(a) or (b) applies, the dose determined by the Secretary is taken to be the dose level mentioned in the item.

 

 

 

 

 

 

 

 

 

Schedule 2     Amendments

 

[1]        Schedule 1, after

 

 

Injection 18 i.u. (6 mg) cartridge with 3.15 mL diluent (with preservative)

Injection

Humatrope

LY

AMP

D

insert:

 

Solution for injection 6 mg (18 i.u.) in 1.03 mL cartridge (with preservative)

Injection

Saizen

SG

AMP

D

 

[2]           Schedule 1, after

 

 

Powder for injection 12 mg (36 i.u.) with diluent in pre-filled pen (with preservative)

Injection

Genotropin GoQuick

PF

AMP

D

insert:

 

Solution for injection 12 mg (36 i.u.) in 1.5 mL cartridge (with preservative)

Injection

Saizen

SG

AMP

D

 

[3]           Schedule 1, after

 

 

Solution for injection 15 mg (45 i.u.) in 1.5 mL cartridge (with preservative)

Injection

Norditropin NordiFlex

NO

AMP

D

 

 

 

Norditropin FlexPro

NO

AMP

D

 

 

 

Norditropin SimpleXx

NO

AMP

D

insert:

 

Solution for injection 20 mg (60 i.u.) in 2.5 mL cartridge (with preservative)

Injection

Saizen

SG

AMP

D

 

1Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the

Legislative Instruments Act 2003.  See http://www.frli.gov.au.